title: Exogenous surfactant decreases oxygenation in Escherichia coli endotoxin-treated neonatal piglets.
abstract: Abnormalities of pulmonary surfactant function have been described in association with the acute respiratory distress syndrome (ARDS). Because gram-negative sepsis is a common cause of ARDS, we treated neonatal piglets with Escherichia coli endotoxin to create a neonatal ARDS model. We hypothesized that under these conditions administration of exogenous surfactant would improve pulmonary function. Study groups included: control (n-8), Exosurf (5 mL/kg, 13.5 mg phospholipid/mL, n-7), Survanta (4 mL/kg, 25 mg phospholipid/mL, n-6), and saline (5 mL/kg, n = 6). E. coli endotoxin 12 micrograms/kg was infused over 30 min and resulted in significant pulmonary and hemodynamic abnormalities, histopathologic evidence of nonhomogeneous lung injury, and elevated protein levels in bronchoalveolar lavage washings. Neither Exosurf nor Survanta ameliorated the pulmonary effects of endotoxin. Instead, there was a prolonged decrease in arterial oxygen tension (PaO2) and dynamic lung compliance after administration of surfactant and saline. Distribution of a bolus of Exosurf was uneven throughout the lung. We conclude that in this neonatal piglet model of ARDS, bolus surfactant administration had a detrimental effect on oxygenation and pulmonary function.
authors.affiliation: Department of Pediatrics, Kapiolani Medical Center for Women and Children, John A. Burns School of Medicine, Honolulu, HI 96826, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Sood
authors.forename: V
authors.initials: V
authors.lastname: Balaraman
authors.forename: K C
authors.initials: KC
authors.lastname: Finn
authors.forename: S Y
authors.initials: SY
authors.lastname: Wilkerson
authors.forename: T G
authors.initials: TG
authors.lastname: Mundie
authors.forename: D
authors.initials: D
authors.lastname: Easa
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001688:Biological Products; D001992:Bronchoalveolar Lavage Fluid; D004195:Disease Models, Animal; D004338:Drug Combinations; D004731:Endotoxins / Q000633:toxicity*; D004926:Escherichia coli; D005233:Fatty Alcohols / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D008168:Lung / Q000473:pathology; D008170:Lung Compliance; D008297:Male; D010100:Oxygen / Q000097:blood; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000009:adverse effects* / Q000627:therapeutic use; D012123:Pulmonary Ventilation; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D013552:Swine; D013997:Time Factors
chemical_list: D001688:Biological Products; D004338:Drug Combinations; D004731:Endotoxins; D005233:Fatty Alcohols; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C044101:endotoxin, Escherichia coli; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; C072197:beractant; D010100:Oxygen